Omd, or osteomodulin, is a proteoglycan involved in extracellular matrix mineralization. It plays a role in bone and cartilage metabolism and is associated with subchondral bone sclerosis, a main feature of osteoarthritis (OA) [1]. Omd is correlated with bone and cartilage microarchitectures, affecting bone volume and the onset of subchondral bone sclerosis and spontaneous cartilage lesions. Mechanistically, it binds to RANKL and inhibits osteoclastogenesis, thus controlling the balance of bone remodeling [1].

Using Omd knockout and overexpressing male mice, researchers found that the expression of Omd is crucial for maintaining the balance of bone remodeling. Its down-regulation is associated with the development of OA, indicating its key role in this disease [1].

In conclusion, Omd is a key factor in subchondral bone sclerosis related to OA. The study of Omd knockout mouse models has revealed its role in bone and cartilage homeostasis by regulating osteoclastogenesis, providing potential new personalized approaches for OA treatment [1].